King Pharmaceuticals, Inc. (King) is a vertically integrated pharmaceutical company that performs basic research and develops, manufactures, markets and sells branded prescription pharmaceutical products and animal health products. King's branded prescription pharmaceuticals include neuroscience products (primarily pain medicines), hospital products and legacy brands, all of which are for use in humans. Its auto-injector business manufactures acute care medicines for use in humans that are delivered using an auto-injector. Its animal health business is focused on medicated feed additives (MFAs) and water-soluble therapeutics primarily for poultry, cattle and swine. King's business consists of four segments: a specialty-driven branded prescription pharmaceuticals business, global animal health business, Meridian auto-injector business, and royalties and other.

Otsuka Pharmaceutical Factory, Inc. manufactures and distributes pharmaceutical and nutritional products. Its products include medical foods, hine E-gel, processlead, engelead, innerpower, oronine h ointment, urepearl plus lotion 10 and urepearl plus cream. The company was founded on September 1, 1921 and is headquartered in Naruto, Japan.

Takeda Pharmaceutical Company Ltd (武田薬品工業株式会社 Takeda Yakuhin Kōgyō Kabushiki-gaisha) is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following merger with Shire). The company has over 30,000 employees worldwide and achieved 16.2 billion USD in revenue during the 2012 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Takeda Oncology. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.

Palo Biofarma SL discovers and develops pharmaceutical products. Its pipeline consists of receptors which target pulmonary diseases, attention-deficit disorders, glaucoma, and degenerative conditions. The company was founded by Juan Camacho Gamez in 2006 and is headquartered in Noáin, Spain.

Manufactures pharmaceuticals

ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company employs technologies, such as its ArQule Kinase Inhibitor Platform (AKIP) to design and develop drugs. The Company's product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase. ARQ 197 is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in Microphthalmia Transcription Factor (MiT) associated tumors, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma and hepatocellular carcinoma (HCC). The Company has licensed commercial rights to ARQ 197 for human cancer indications to Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) in the United States, Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin).

Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. Its product pipeline include Piclidenoson, Namodenoson, and CF602. The company was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach-Tikva, Israel.

Researches, develops, and licenses cardiovascular medicines and adenosine-based products

Manufactures pharmaceuticals for cardiovascular treatment, central nervous system, internal medicine drugs and oncology treatment

GlyTech, Inc. engages in providing drug discovery and biologics services and pharmaceutical ingredients. The firm conducts drug discovery utilizing its platform technologies and provides innovative biologics and pharmaceutical ingredients based on the chemical synthetic methods for proteins and peptides through glyco-science and -technology. GlyTech offers custom synthesis services, research and development collaborations, and deal structures: upfront, milestones and royalties. The company was founded on April 2, 2012 and is headquartered in Kyoto, Japan.

Otsuka Chemical Co., Ltd. engages in the production of chemicals and diet supplements. It provides inorganic salts, bromides, hydrazine, foaming agent, polymerization initiator, preparation articles, rust-preventive agent, fire retarding material, intermediates, and electro-organic synthesis products. The company was founded on August 29, 1950 and is headquartered in Tokyo, Japan.

Faust Pharmaceuticals

Manufactures, marketes and imports, exports pharmaceutical drugs

OSI Pharmaceuticals strives to improve the health and quality of life for patients, develop breakthrough treatment options for physicians, offer rewarding careers to employees, and deliver value to our shareholders. The strategy is to build on the success of our flagship product, Tarceva® (erlotinib), and continue to invest in clinical and pre-clinical drug candidates in oncology, diabetes and obesity to provide longer-term growth. OSI has evolved to become a scientifically strong and financially successful top-tier biopharmaceutical company that is focused on disease areas that impact virtually every family in the world. The Oncology team is dedicated to the discovery and development of molecular targeted therapies to revolutionize the way cancer is treated and improve treatment outcomes. The Diabetes & Obesity team is dedicated to the discovery and development of novel drugs for the treatment of type 2 diabetes and obesity. The strategy for this business team is to advance a pipeline of innovative diabetes and obesity research projects through clinical proof-of-concept studies, with a view to then potentially seeking financially attractive development and commercialization partnerships for these research programs. The goal is to pave the way for the future of oncology, diabetes and obesity treatments. They believe that our Company strategy is poised to deliver a rich pipeline of promising drug candidates that have the potential to significantly improve the treatment options available to patients today.

Sanofi A/S engages in the production of prescription drugs as well as participates in clinical trials of present and future products. It specializes in diabetes, oncology, multiple sclerosis, rare disease and cardio vascular illnesses. The company is headquartered in Copenhagen, Denmark.

Abbott Products SAS provides pharmaceutical products. The company is headquartered in Suresnes, France.

Genaissance Pharmaceuticals, Inc. develops and uses genetic information to diagnostic and therapeutic products. The company was founded by Kevin L. Rakin and Gualberto Ruano in 1992 and is headquartered in New Haven, CT.

The Group's principal activity is to produce pharmaceuticals and chemicals. The operations are carried out through the following divisions: Pharmaceuticals; Bio chemical; Chemicals; Food and Other. Pharmaceuticals include ethical drugs, bulk pharmaceuticals and biological research. Bio chemicals deal with biochemical diagnostic reagents, animal health products, agrochemicals and fertilizers. Chemicals includes solvents, plasticizes and their raw materials, detergent raw materials and specialty chemicals. Food includes alcoholic beverages, alcohol, seasonings, confectionery, baking ingredients and processed foods. Others include wholesale, commodity distribution and installation of facilities.